Evidence map›Paper›PMID 26088927›Full record

Trial reportHaematologica2015

Renal complications in chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis: the Mayo Clinic experience.

Paolo Strati, Samih H Nasr, Nelson Leung, Curtis A Hanson, Kari G Chaffee, Susan M Schwager, Sara J Achenbach, Timothy G Call, Sameer A Parikh, Wei Ding and 2 more

Open access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Haematologica, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 1 pooled it
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 1 synthesis or guideline pooled it, 103 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Fitness in CLL.Cancers · 2026
    Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Paolo StratiMayo Clinic College of Medicine, Rochester, MN, USA.
Samih H NasrMayo Clinic College of Medicine, Rochester, MN, USA.
Nelson LeungMayo Clinic College of Medicine, Rochester, MN, USA.
Curtis A HansonMayo Clinic College of Medicine, Rochester, MN, USA.
Kari G ChaffeeMayo Clinic College of Medicine, Rochester, MN, USA.
Susan M SchwagerMayo Clinic College of Medicine, Rochester, MN, USA.
Sara J AchenbachMayo Clinic College of Medicine, Rochester, MN, USA.
Timothy G CallMayo Clinic College of Medicine, Rochester, MN, USA.
Sameer A ParikhMayo Clinic College of Medicine, Rochester, MN, USA.
Wei DingMayo Clinic College of Medicine, Rochester, MN, USA.
Neil E KayMayo Clinic College of Medicine, Rochester, MN, USA.
Tait D ShanafeltMayo Clinic College of Medicine, Rochester, MN, USA shanafelt.tait@mayo.edu.
Mayo Clinic · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While the renal complications of plasma cell dyscrasia have been well-described, most information in patients with chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis is derived from case reports. This is a retrospective analysis of patients with chronic lymphocytic leukemia or monoclonal B-cell lymphocytosis who underwent kidney biopsy for renal insufficiency and/or nephrotic syndrome. Between January 1995 and June 2014, 49 of 4,024 (1.2%) patients with chronic lymphocytic leukemia (n=44) or monoclonal B-cell lymphocytosis (n=5) had a renal biopsy: 34 (69%) for renal insufficiency and 15 (31%) for nephrotic syndrome. The most common findings on biopsy were: membranoproliferative glomerulonephritis (n=10, 20%), chronic lymphocytic leukemia interstitial infiltration as primary etiology (n=6, 12%), thrombotic microangiopathy (n=6, 12%), and minimal change disease (n=5, 10%). All five membranoproliferative glomerulonephritis patients treated with rituximab, cyclophosphamide and prednisone-based regimens had recovery of renal function compared to 0/3 patients treated with rituximab with or without steroids. Chronic lymphocytic leukemia infiltration as the primary cause of renal abnormalities was typically observed in relapsed/refractory patients (4/6). Thrombotic microangiopathy primarily occurred as a treatment-related toxicity of pentostatin (4/6 cases), and resolved with drug discontinuation. All cases of minimal change disease resolved with immunosuppressive agents only. Renal biopsy plays an important role in the management of patients with chronic lymphocytic leukemia or monoclonal B-cell lymphocytosis who develop renal failure and/or nephrotic syndrome.

Indexed as

Leukemia, Lymphocytic, Chronic, B-CellLymphocytosisNephrotic SyndromePentostatinRenal InsufficiencyFemaleFollow-Up StudiesHumansMaleRetrospective StudiesRituximabPentostatinRituximab

Identifiers

PMID26088927
PMCPMC4800708
OpenAlexW2176746630

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.